Ignite Creation Date:
2024-05-05 @ 10:51 PM
Last Modification Date:
2024-10-26 @ 10:25 AM
Study NCT ID:
NCT01202591
Status:
COMPLETED
Last Update Posted:
2016-02-11
First Post:
2010-09-14
Brief Title:
Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs Fulvestrant Alone in ER Breast Cancer Patients
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomised Double-blind Phase IIa Study With Combination Safety Run-in to Assess the Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs Fulvestrant Alone in ER Breast Cancer Patients With FGFR1 Polysomy or Gene Amplification Who Have Progressed Following Treatment With Prior Endocrine Therapy Adjuvant or First-line Metastatic GLOW
Status:
COMPLETED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GLOW
Brief Summary:
The purpose of this study is to assess the safety and effectiveness of AZD4547 in combination with fulvestrant vs fulvestrant alone in ER breast cancer patients with FGFR1 polysomy FISH45 or gene amplification FISH 6
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2010-021220-10 | EUDRACT_NUMBER | None | None |